Jump Financial’s Faeth Therapeutics FTH Stock Holding History

Jump Financial’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-590	Closed	-$68K	–	1883
2021 Q4	$68K	Buy	+590	New	+$88.2K	﹤0.01%	1273

Other funds holding FTH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Jump Financial's FTH Position: Q1 2022 in Review

Jump Financial sold out of Faeth Therapeutics (FTH) in Q1 2022, closing a stake of 590 shares — an estimated $68K sold.

Jump Financial first reported a position in FTH in Q4 2021 and held it in 1 quarter. The position peaked at $68K in Q4 2021. 42 funds tracked by Wall St. Rank hold FTH as of Q1 2022.

Jump Financial reported no remaining Faeth Therapeutics position as of Q1 2022 after selling out during the quarter.
Jump Financial sold 590 Faeth Therapeutics shares in Q1 2022, an estimated $68K.
Jump Financial first reported a position in Faeth Therapeutics in Q4 2021 and held it in 1 quarter.
Jump Financial's Faeth Therapeutics position peaked at $68K in Q4 2021.
42 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2022.

Based on Jump Financial's 13F filing for Q1 2022, filed 12 May 2022.